Kornimate/medical-research-clean huggingface dataset:
corrected measurement of the retinal nerve fiber layer thickness by optic disc configuration with the cirrus hd oct

Conditions: Glaucoma; Myopia

Summary: because the measurement of the retinal nerve fiber layer thickness is very sensitive to the position of measurement, it may be incorrect in patients with the tilted disc. in the present study, the corrected rnfl thickness by the optic nerve head configuration using the cirrus hd oct will be evaluated. if the corrected rnfl thickness is more sensitive to detect the localized rnfl defect, the present software should be upgrade to reflect the optic nerve head configuration.

finding the localized retinal nerve fiber layer (rnfl) defect and measuring the rnfl thickness are two main issues for early glaucoma detection. a recently developed imaging device, the cirrus hd oct, offers more detailed informations about retina architecture including optic nerve head. to calculate the rnfl thickness, the software of the cirrus hd oct supposes an ideal optic nerve head. however, in the cases with not ideal optic disc configuration, the measurement of the rnfl thickness is not correct. because the measurement of the rnfl thickness is extremely sensitive to the position of measurement, patients with the tilted disc are in danger of misdiagnosis. in the present study, we want to correct the rnfl thickness measurement according to the optic nerve head configuration using the cirrus hd oct. if the corrected rnfl thickness is more sensitive to detect the localized rnfl defect, the present software should be upgrade to reflect the optic nerve head configuration.

Eligibility criteria:
inclusion criteria: * normal controls or glaucoma patients * signal intensity of the oct image \> 8 * cooperative subjects exclusion criteria: * spherical equivalent refractive errors \> +4 diopters or \< -4 diopters * significant media opacity * previous intraocular surgery

Keywords: retinal nerve fiber layer optic nerve head cirrus oct
urology database for outcomes research

Conditions: Prostate Cancer; Pelvic Pain; Incontinence

Summary: the purpose of initiating the urology database is to collect relevant retrospective data via chart review related to patients undergoing radical prostatectomy via the retropubic, perineal, laparoscopic, and robotic assisted laparoscopic approaches and interstim implantation. this data will be utilized to evaluate the health benefits and outcomes of each of these procedures to enhance care and treatment.

the objective of this study is to initiate and maintain a patient information database that will be used to study the impact of each surgical procedure on patients' overall health, quality of life, and bowel/bladder/sexual function. the study coordinator will, on an ongoing basis, abstract needed medical information from inpatient hospital and physician office records for inclusion into the database.

Eligibility criteria:
inclusion criteria: * all patients undergoing radical prostatectomy or interstim implantation at william beaumont hospital. exclusion criteria: * none

Keywords: prostate cancer prostatectomy pelvic pain urgency incontinence frequency
establishing effective screening methods for diagnosing hereditary nonpolypoisis colorectal cancer

Conditions: Colonic Neoplasms

Summary: correct identification of lynch syndrome at the time of colorectal cancer presentation is important. we aim to find best ways to screen patients with colorectal cancer in korea.

patients with newly diagnoised colorectal cancer will be eligible. they will undergo detailed history taking including family history, and molecular stuidies including microsatellite instability test and immunohistochemistry for dna mismatch repair protein with pre-selection. any abnormal finding in molecular stuides will be offered genetic testing (after testing methylation status for patients with abnormalities in mlh1).

Eligibility criteria:
inclusion criteria: * colorectal cancer exclusion criteria: * histology showing other than adenocarcinoma

Keywords: colonic neoplasms lynch syndrome
rs-fmri to nutrient shakes

Conditions: Pleasure

Summary: resting state functional magnetic resonance imaging (rsfmrl) of the brain is used to measure pleasantness after consumption of four different milkshakes with added sugars or sweeteners.

the central role of the brain in regulating food intake and steering feeding behaviour is increasingly recognized. it is currently well accepted that the brain is the target organ to measure the effects of pleasantness and energy homeostasis in order to change feeding behaviour to reduce the rising prevalence of obesity. the effects of food on the brain are multiple and complex. in addition to primary aspects of food such as taste, texture, looks and smell, secondary aspects such as energy regulation are as much important in the entire "eating experience". resting state functional connectivity in the brain can be assessed by the analysis of low-frequency fluctuations present in the blood-oxygenation-level-dependent (bold) signal in functional magnetic resonance imaging (fmri). investigators will use resting state functional magnetic resonance imaging (rsfmrl) to detect changes in connectivity in the default mode and salience network after consumption of four different milkshakes with added sugars or sweeteners.

Eligibility criteria:
inclusion criteria: * signed informed consent * age between 18 and 25 years * bmi between 20 and 23 kg/m2 * weight above 70 kg * length between 170 and 190 centimetres exclusion criteria: * diabetes or history of other disturbances of glucose metabolism (eg impaired glucose tolerance, hypoglycaemia). * any genetic or psychiatric disease (e.g. fragile x syndrome, major depression) affecting brain * any know food allergy or intolerance * any significant chronic disease * renal or hepatic disease * recent weight changes or attempts to lose weight (\> 3 kg weight gain or loss, within the last 3 months) * smoking (current or last 6 months) * alcohol consumption of more than 21 units per week or use of recreational drugs at present or in the last year * recent blood donation (within the last 2 months) * recent participation in other biomedical research projects (within the last 3 months), participation in 3 or more biomedical research projects in one year * contra-indication to mri scanning: * claustrophobia * pacemakers and defibrillators * nerve stimulators * intracranial clips * intraorbital or intraocular metallic fragments * cochlear implants * ferromagnetic implants
evaluate the efficacy and safety of co-administration of jw0104+c2402 in patients with hypertension and dyslipidemia

Conditions: Hypertension; Dyslipidemia

Summary: a multi-center, randomized, double-blind, parallel, phase ⅲ clinical trial to evaluate the efficacy and safety of co-administration of jw0104+c2402 in patients with hypertension and dyslipidemia

to evaluate the efficacy and safety of co-administration of jw0104+c2402 in comparison with co-administration of jw0104+c2403 or c2402 alone in patients with hypertension and dyslipidemia.

Eligibility criteria:
inclusion criteria: * patients with hypertension and dyslipidemia exclusion criteria: * the subject not meet the specified msbp and ldl-c level
exercise intolerance in post-covid patients

Conditions: Post-COVID Syndrome

Summary: the post-covid syndrome poses an unprecedented challenge to modern society, affecting millions of people worldwide. persistent fatigue and exercise intolerance are among the most common complaints of these subjects. the mechanisms of exercise intolerance in post-covid subjects are remained yet unknown, which make the rehabilitation efforts complex and challenging. the overall goals of this project are to: 1) improve physiological understanding of symptoms in this clinical condition, 2) elucidate plausible mechanisms to explain exercise intolerance/symptom exacerbation, and finally 3) provide knowledge that can be directly applied in the clinical setting to improve diagnosis, care, and individualized rehabilitation of subjects with post-covid syndrome. post-covid subjects and age/sex matched healthy controls will undertake a comprehensive set of physiological and functional assessments, followed by 3 experimental visits (in a randomized order), where acute exercise responses will be assessed in either continuous moderate intensity aerobic exercise, high intensity interval exercise, or strength training. the same set of physiological assessments will also be performed after 1 year in both post-covid subjects and healthy-matched controls to better understand the time course of the syndrome. it is hypothesized that the mechanism responsible for exercise intolerance is linked to specific symptoms and will vary across subjects. however, it is expected that most post-covid subjects will respond well to at least one type of exercise.


Eligibility criteria:
inclusion criteria: * verified test of covid-19 infection (pcr, or antigen or antibody before vaccination) (mandatory only for post-covid group) * symptoms persisting for at least 3 months (validaded with dsq-pem questionnarie) (only for post-covid group) exclusion criteria: * subject's complaints may have been present before march 2020 * previous history cardiovascular, respiratory disease or other autoimmune disease * history of general anxiety syndrome or somatic symptom disorder

Keywords: exercise intolerance acute exercise skeletal muscle cardiorespiratory fitness post-covid syndrome
the development and application of "scar-care" padding on management of hypertrophic scar

Conditions: Cicatrix, Hypertrophic; Rehabilitation

Summary: this study explores the smart scar care pad's potential therapeutic effect in treatment hypertrophic scar while elucidating the adverse effects if there is any. half of the participant receives traditional treatment of pressure garment and the other half receives the smart scar care pad together with pressure garment.


Eligibility criteria:
inclusion criteria: 1. subjects with hypertrophic scar(hs); 2. the hs had a total vancouver scar scale (vss) score of 4 or higher and the score of each item equal to or greater than 1; 3. subjects age between 20 and 70 years, cooperative, and good compliance with treatment. exclusion criteria: 1. the hs area had an open wound or infection; 2. the hs had been treated with steroid injections or other intervention (such as traditional chinese medicine or laser therapy) before the study; or 3. the patient had a medical condition that might affect wound healing (e.g., diabetes mellitus or another serious medical problem).

Keywords: insert pressure therapy silicone gel
the study of gut associated lymphocytes in hiv and hcv/hiv co-infected patients

Conditions: HIV; Hepatitis C, Chronic; HCV Coinfection

Summary: the purpose of this research study is to explore what role immune cells within the gut (the sigmoid colon) have locally and on the immune system of patients infected with hcv, hiv or hcv/ hiv co-infection.

objective 1: characterization of the gut associated lymphocytes (galt) in hiv, hcv and coinfected patients regarding the role of th17 and cytokine profiles. hypothesis 1a: hiv and hcv/hiv coinfection is associated with changes in th17 numbers and functions in galt. hypothesis 1b: hiv and hcv/hiv coinfection is associated with changes in cytokine profiles in intestinal mucosa. objective 2: identify the relationship between changes in gut associated lymphocytes (galt) in hiv, hcv and coinfected patients and markers of microbial translocation. hypothesis 2a: changes in galt are associated with increase in microbial translocation in hiv, hcv and coinfected patients.

Eligibility criteria:
inclusion criteria: * are at least age 18, but not older than 70 years old * have hiv, hcv or both * do not have hiv, hcv or both, and are having a screening colonoscopy or flexible sigmoidoscopy for abdominal pain or colon cancer screening (control subject) exclusion criteria: * have a history of inflammatory bowel diseases (ibd) or suspected ibd * have a history of autoimmune diseases including rheumatoid arthritis * are taking systemic immunomodulators * are pregnant

Keywords: hiv hcv hepatitis c hiv and hepatitis c coinfection hiv/hcv
avastin and doxorubicin postoperatively for patients with anaplastic thyroid cancer

Conditions: Thyroid Neoplasms; Carcinoma; Thyroid Cancer; Metastatic Cancer

Summary: anaplastic thyroid cancer is a very aggressive disease. the investigators believe that angiogenesis is very important for these tumors to progress. preclinical data is suggesting this. this is why we we prospectively want to treat these patients with avastin (and doxorubicin). however, local control is of major concern. therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. then they can enter this study.

patients with anaplastic thyroid cancer have a poor prognosis. we will treat the patients initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed dose/week and hyperfractionated radiotherapy 1,6 gy twice daily up to 46 gy in total. the first week during radiotherapy, they will also receive avastin 15mg/kg. 1-2 weeks after radiotherapy patients will undergo surgery of their primary tumor. after this "standard" therapy patients can be included in this study. treatment is 20 mg fixed dose doxorubicin q1w and avastin 15mg/kg q3w. treatment will continue maximum 6 months or until progress or until intolerable side effects occur.

Eligibility criteria:
inclusion criteria: * cytologically or histologically verified anaplastic thyroid cancer * completed standard therapy * operated with r0 or r1 surgery * performance status 0-2 (if pulmonary mets ps 0-1) * normal wound healing * neutrophils \> 1,5 million/ml * platelets \> 100 million/ml * bilirubin \< 2 uln * creatinin \< 150mikromol/l exclusion criteria: * ps 3-4 (if pulmonary mets 2-4) * r2 resection of primary tumor

Keywords: adjuvant anaplastic thyroid cancer
study evaluating the safety and efficacy of rap-219 in adult participants with refractory focal epilepsy

Conditions: Focal Onset Seizures

Summary: this is a clinical research study for an investigational drug called rap-219 in patients with refractory focal epilepsy. this study is being conducted to determine if rap-219 works and is safe in patients with refractory focal epilepsy.

this is a phase 2a, proof-of-concept, multi-center, open-label study designed to evaluate the efficacy, safety, tolerability, and pk/pd relationship of rap-219 in adult participants with refractory focal epilepsy. the activity of rap-219 will be assessed in approximately 20 participants treated with the rns® system.

Eligibility criteria:
inclusion criteria: * medically refractory focal epilepsy with an implanted responsive neurostimulator device placed correctly in a seizure onset zone that meet several device-related criteria and demonstrated history of compliance with interrogation of the rns device and upload of data * if currently treated with antiseizure medications, up to a maximum of 4 concomitant mediations are allowed * at least 1 clinical seizure during the 8-week retrospective eligibility period * participants in otherwise good health as determined by the investigator * willing and able to adhere to all aspects of the protocol * a demonstrated history of compliance with interrogation of the rns device and upload of data before screening exclusion criteria: * participants with generalized onset seizures in the past 10 years * history of status epilepticus while on antiseizure medications within 2 years of screening * individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods * participants who have had epilepsy surgery within the last 12 months before screening

Keywords: epilepsy rns long episode fos refractory focal epilepsy
comparing amlodipine/atorvastatin co-administration to amlodipine alone in patients with hypertension and dyslipidemia

Conditions: Hypertension; Hyperlipidemia

Summary: to evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .


Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of both hyperlipidemia and hypertension. exclusion criteria: * subjects with type 1 diabetes mellitus or type 2 diabetes mellitus. * subjects with other atherosclerotic disease.
head position monitoring after pars planar vitrectomy

Conditions: Retinal Detachment; Macular Hole

Summary: in ophthalmic surgical practice, particularly for treating retinal detachment and macular hole disorders, vitrectomy procedures are routinely performed to remove the vitreous body followed by the injection of tamponade agents such as gaseous compounds (e.g., c3f8 or sf6) or silicone oil. these tamponade materials function by creating internal pressure against the retinal surface to facilitate reattachment. a critical determinant of surgical success in these cases is postoperative head positioning (prone posturing), as improper alignment may compromise the tamponade effect. at the investigators' institution, participants undergoing such procedures are prescribed a strict prone position regimen for 7 consecutive postoperative days. this facedown positioning protocol aims to optimize interfacial contact between the tamponade agent and retinal tissue. however, conventional clinical practice faces a significant limitation: the inability to objectively verify patient compliance with prescribed postural guidelines outside clinical settings. subjective patient reporting and intermittent clinical observations prove insufficient for quantifying adherence levels. to address this critical gap in postoperative monitoring, the investigators propose implementing a novel electronic monitoring system integrated into therapeutic eye patches. this advanced device incorporates a miniaturized triaxial gyroscopic sensor array capable of continuously tracking cephalo-cervical orientation with high angular resolution. the system features complete electrical isolation from ocular tissues while maintaining sterility. data acquisition occurs through a microsd card (capacity: 16gb) that logs positional parameters at 0.2hz sampling frequency, creating comprehensive temporal records of head movement patterns.


Eligibility criteria:
inclusion criteria: * patients who get vitrectomy exclusion criteria: * patients who cannot maintain positioning due to their physical disability
efficacy of omalizumab in adults (18-60 years of age) with moderate-severe, persistent allergic asthma, despite receiving inhaled corticosteroids and long acting beta-agonists

Conditions: Allergic Asthma

Summary: this study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics with persistent symptoms and evidence of airway inflammation despite treatment with inhaled corticosteroids and long acting beta-agonists. this study will also investigate the correlation between systemic and pulmonary inflammation, and the correlation between clinical outcomes and changes within the tissue, to assist in the future identification of patients with tissue eosinophilia and their response to treatment, without the need for invasive bronchoscopy.


Eligibility criteria:
inclusion criteria: * patients 18-75 years of age with moderate to severe persistent allergic asthma receiving a high dose inhaled corticosteroid (≥800µg per day bdp or equivalent) and a regular long acting beta-agonist for at least 3 months prior to screening * with a body weight between 20 and 150kg and a serum total ige level of 30 to 700 iu/ml * with ≥2% eosinophilia in induced sputum at screening * with post-bronchodilator forced expiratory volume in 1 second (fev1) ≥60% predicted * with a positive skin prick test (diameter of wheal ≥ 3 mm) or rast test to at least one perennial aero-allergen (eg. dust mite, cat/dog dander, cockroaches), documented within the past 2 years or demonstrated at visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study. exclusion criteria: * patients who've had an asthma exacerbation during the 4 weeks prior to randomization * current smokers, stopped smoking within the last 12 months or have a smoking history of \>10 pack years * history of severe allergy to food or drugs * previous treatment with omalizumab * any patient considered to be unsuitable to bronchoscopy, according to the judgment of the investigator other protocol-defined inclusion/exclusion criteria applied.

Keywords: asthma, adults, anti-immunoglobulin e ( ige), omalizumab, airway inflammation, airway remodeling, allergy
a novel approach to optimize programmed intermittent epidural bolus (pieb) delivery for labour analgesia

Conditions: Labor Pain

Summary: programmed intermittent epidural bolus (pieb) for labour analgesia allows an epidural pump to be programmed to deliver small amounts of the local anesthetic and opioid solution at regularly timed intervals. however, little evidence is available to guide optimal settings for pieb. the gaps in evidence include: (1) programmed timing for the first pieb bolus (referred to as the "next bolus") (2) determination of pieb bolus volume (3) the interval for subsequent doses (pieb interval). response surface methodology will be utilized to best estimate the optimal pieb settings (next bolus interval, pieb interval time, pieb volume) by using the following clinical primary outcome measures: maternal satisfaction score, need for a clinician administered rescue bolus, and the ratio of pcea boluses requested/delivered.


Eligibility criteria:
inclusion criteria: * nulliparous, * english speaking * 18-45 years * single gestation ≥ 37 weeks * vertex presentation * american society of anesthesiologists (asa) physical status ii (mild and controlled systemic disease and/or pregnancy) * requesting an epidural for labour analgesia * cervical dilation ≤ 7 cm at the time of initiation of epidural analgesia. exclusion criteria: * preeclampsia or hellp syndrome * maternal cardiac disease * severe or uncontrolled maternal systemic disease * contraindication to neuraxial analgesia (i.e. coagulopathy, infection, neuropathy) * abnormal spinal anatomy (i.e. severe scoliosis, spina bifida, spinal instrumentation) * chronic analgesic use * a physical or psychiatric condition which may impair cooperation * known fetal anomalies/intrauterine fetal demise * height \< 5'0" * body mass index \> 45 kg/m2

Keywords: analgesia epidural labor obstetric analgesia obstetrical